Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works to treat ALS. Participants will: Take pridopidine or a placebo by mouth every day for 48 weeks. Afterwards, all participants will take pridopidine for another 48 weeks. Visit the clinic once every 1-3 months for checkups and tests

Participants needed: 500
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: PrileniaUpdated: Jul 2, 2026Locations: 32
Eligibility criteria

Definite ALS or Probable ALS using the El Escorial criteria. [+4]

Presence of tracheostomy or permanent assisted ventilation. [+7]

Status: Not yet recruiting

Pridopidine Phase 3 Study in Huntington's Disease

The goal of this clinical trial is to learn if pridopidine can slow the clinical decline of Huntington's Disease (HD) in adult participants. It will also inform about the safety of pridopidine. The main questions the study aims to answer are: Does pridopidine slow the overall worsening of HD over 1 year? Does pridopidine slow the worsening of specific aspects of HD over 1 year, namely the clinical progression, the ability to perform daily life activities (functional capacity), the mind's ability to process information (cognition), working of the muscles (motor function), and quality of life? Researchers will compare the drug pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works better than placebo to treat HD. During the first year of the study, participants will have the same chance to receive either pridopidine or placebo. Participants will: Take 1 pridopidine or placebo capsule twice daily for 12 months. Visit the clinic 6 times within 1 year for checkups and tests. All participants who complete this 1-year placebo-controlled study period will roll over into an additional 2-year study period during which all participants will receive pridopidine treatment, including participants who had received placebo during the first year. During this additional 2-year treatment period participants will visit the clinic a total of 6 times for checkups and tests.

Participants needed: 400
Trial details
Phase: Phase 3Age: 23-65Biological sex: AllType: InterventionalSponsor: PrileniaUpdated: Jun 2, 2026
Eligibility criteria

Adult-onset HD (onset of signs and symptoms and a clinical diagnosis at ≥21 year... [+7]

Clinically significant cardiovascular disease (e.g. QTcF >450 msec [males] or >4... [+7]